FDA Panel Split on Safety of Long-Acting Testosterone

//FDA Panel Split on Safety of Long-Acting Testosterone

FDA Panel Split on Safety of Long-Acting Testosterone

Article Title: FDA Panel Split on Safety of Long-Acting Testosterone

Author: Megan Brooks

Date of Publication: April 18, 2013

An advisory panel to the US Food and Drug Administration (FDA) was split today on the question of whether or not testosterone undecanoate intramuscular injection (Aveed, Endo Pharma Solutions) is a safe testosterone replacement therapy, given reports of severe post-injection reactions.

Read More
Note:  This MedScape article requires that you setup a free account to view the article.

2018-07-25T20:43:13+00:00Categories: 47,XXY (Klinefelter)|